Trial Profile
DEP-ruxolitinib Regimen as a Salvage Therapy for Refractory/Relapsed Hemophagocytic Lymphohistiocytosis
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Etoposide (Primary) ; Methylprednisolone (Primary) ; Ruxolitinib (Primary)
- Indications Haemophagocytic lymphohistiocytosis
- Focus Therapeutic Use
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 17 May 2018 New trial record